Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

Imagem de Miniatura
Arquivos
art_FORLENZA_Clinical_and_biological_effects_of_longterm_lithium_treatment_2019.PDF.pdf (339.27 KB)
Citações na Scopus
99
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CAMBRIDGE UNIV PRESS
Autores
Citação
BRITISH JOURNAL OF PSYCHIATRY, v.215, n.5, p.668-674, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Experimental studies indicate that lithium may facilitate neurotrophic/protective responses in the brain. Epidemiological and imaging studies in bipolar disorder, in addition to a few trials in Alzheimer's disease support the clinical translation of these findings. Nonetheless, there is limited controlled data about potential use of lithium to treat or prevent dementia. Aims To determine the benefits of lithium treatment in patients with amnestic mild cognitive impairment (MCI), a clinical condition associated with high risk for Alzheimer's disease. Method A total of 61 community-dwelling, physically healthy, older adults with MCI were randomised to receive lithium or placebo (1:1) for 2 years (double-blind phase), and followed-up for an additional 24 months (single-blinded phase) (trial registration at clinicaltrials.gov: NCT01055392). Lithium carbonate was prescribed to yield subtherapeutic concentrations (0.25-0.5 mEq/L). Primary outcome variables were the cognitive (Alzheimer's Disease Assessment Scale - cognitive subscale) and functional (Clinical Dementia Rating - Sum of Boxes) parameters obtained at baseline and after 12 and 24 months. Secondary outcomes were neuropsychological test scores; cerebrospinal fluid (CSF) concentrations of Alzheimer's disease-related biomarkers determined at 0, 12 and 36 months; conversion rate from MCI to dementia (0-48 months). Results Participants in the placebo group displayed cognitive and functional decline, whereas lithium-treated patients remained stable over 2 years. Lithium treatment was associated with better performance on memory and attention tests after 24 months, and with a significant increase in CSF amyloid-beta peptide (A beta(1-42)) after 36 months. Conclusions Long-term lithium attenuates cognitive and functional decline in amnestic MCI, and modifies Alzheimer's disease-related CSF biomarkers. The present data reinforces the disease-modifying properties of lithium in the MCI-Alzheimer's disease continuum. Declaration of interest None.
Palavras-chave
Alzheimer's disease, mild cognitive impairment, treatment, clinical trial, lithium
URI
https://observatorio.fm.usp.br/handle/OPI/35513
Referências
  1. [Anonymous], 1944, ARM IND TEST BATT MA
  2. Aprahamian I, 2014, J CLIN PSYCHIAT, V75, pE672, DOI 10.4088/JCP.13m08741
  3. Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x
  4. Dell'Osso L, 2016, NEUROPSYCH DIS TREAT, V12, P1687, DOI 10.2147/NDT.S106479
  5. Fajardo VA, 2018, J ALZHEIMERS DIS, V61, P425, DOI 10.3233/JAD-170744
  6. Forlenza OV, 2014, ACS CHEM NEUROSCI, V5, P443, DOI 10.1021/cn5000309
  7. Forlenza OV, 2016, CURR ALZHEIMER RES, V13, P879, DOI 10.2174/1567205013666160219112854
  8. Forlenza Orestes V, 2015, Alzheimers Dement (Amst), V1, P455, DOI 10.1016/j.dadm.2015.09.003
  9. Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044
  10. Hajek T, 2012, J PSYCHIATR NEUROSCI, V37, P185, DOI 10.1503/jpn.110097
  11. Hampel H, 2009, J CLIN PSYCHIAT, V70, P922, DOI 10.4088/JCP.08m04606
  12. Kessing LV, 2008, ARCH GEN PSYCHIAT, V65, P1331, DOI 10.1001/archpsyc.65.11.1331
  13. Kessing LV, 2017, JAMA PSYCHIAT, V74, P1005, DOI 10.1001/jamapsychiatry.2017.2362
  14. Lingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1
  15. Macdonald A, 2008, INT J GERIATR PSYCH, V23, P704, DOI 10.1002/gps.1964
  16. Matsunaga S, 2015, J ALZHEIMERS DIS, V48, P403, DOI 10.3233/JAD-150437
  17. Moore GJ, 2000, LANCET, V356, P1241, DOI 10.1016/S0140-6736(00)02793-8
  18. Morris G, 2016, CURR ALZHEIMER RES, V13, P853, DOI 10.2174/1567205013666160219113112
  19. MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a
  20. Nunes MA, 2013, CURR ALZHEIMER RES, V10, P104
  21. Nunes PV, 2007, BRIT J PSYCHIAT, V190, P359, DOI 10.1192/bjp.bp.106.029868
  22. Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303
  23. Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640
  24. ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356
  25. Wechsler D., 1977, WECHSLER ADULT INTEL
  26. Zung S, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.97

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/27